A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study

Clinical and Translational Oncology

Volumn 13, Issue 9, 2011, Pages 686-691

  Antolín, Silvia ^a   Mel, Ramón ^b   Ramos, Manuel ^c   García Palomo, Andrés ^d   Almanza, Concepción ^e   Paz, Laura ^f   Calvo, Lourdes ^a   Álvarez, Elena ^b   González, Ana ^c   García Mata, Jesús ^g,h  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c Cent Oncol Reg   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

^e HOSPITAL POVISA   (Spain)

^f Universidad de La Coruña   (Spain)

^g Hospital Santa Maria Nai   (Spain)

^h Medical Oncology Department   (Spain)

Author keywords

Breast carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Neoadjuvant; Taxane

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; INTRADUCTAL CARCINOMA; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RASH; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; BREAST TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; PAGET NIPPLE DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 84855362020     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0715-9     Document Type: Article

References (29)

1. Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600-2608 (Pubitemid 46606344)
2. Formenti SC, Volm M, Skinner KA et al (2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21:864-870 (Pubitemid 46606446)
3. van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237
4. Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100 (Pubitemid 28041584)
5. Belembaogo E, Feillel V, Chollet P et al (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A:896-900
6. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469 (Pubitemid 29075229)
7. Scholl SM, Fourquet A, Asselain B et al (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A:645-652 (Pubitemid 24164252)
8. Makris A, Powles TJ, Ashley SE et al (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184 (Pubitemid 28552806)
9. Mamounas EP (1998) Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 25:31-35 (Pubitemid 28188642)
10. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: fi ndings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493 (Pubitemid 27289876)
11. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685 (Pubitemid 28363030)
12. Nabholtz JM, Gligorov J (2005) Docetaxel in the treatment of breast cancer: current experience and future prospects. Expert Rev Anticancer Ther 5: 613-633 (Pubitemid 41223270)
13. Costa SD, von Minckwitz G, Raab G et al (1999) The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 26: 24-31 (Pubitemid 29340754)
14. Goble S, Bear HD (2003) Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 83:943-971 (Pubitemid 36841918)
15. Hutcheon AW, Heys SD, Sarkar TK (2003) Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 79[Suppl 1]: S19-S24 (Pubitemid 36801907)
16. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174 (Pubitemid 46606185)
17. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027 (Pubitemid 46622110)
18. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685 (Pubitemid 46179457)
19. Norton L (1997) Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-3-S10-10
20. Norton L (1999) Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 26: 11-20 (Pubitemid 29153681)
21. Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6[Suppl 3]:30-35 (Pubitemid 32423184)
22. Gianni L, Mariani G, Mariani P (2004) Role of dose in the treatment of breast cancer. Ann Oncol 15[Suppl 4]:iv31-iv35 (Pubitemid 39585310)
23. von Minckwitz G, Costa SD, Eiermann W et al (1999) Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005 (Pubitemid 29318827)
24. -(1999) Common Toxicity Criteria, Version 2.0. National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, June 1
25. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
26. Cristofanilli M, Buzdar AU, Sneige N et al (2001) Paclitaxel in the multimodality treatment for infl ammatory breast carcinoma. Cancer 92:1775-1782 (Pubitemid 32952495)
27. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466 (Pubitemid 34260523)
28. Cooper BW, Radivoyevitch T, Overmoyer BA et al (2006) Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 97:311-318 (Pubitemid 43948219)
29. Miller KD, McCaskill-Stevens W, Sisk J et al (1999) Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037 (Pubitemid 29470630)